Scinai Gets Italian Government Clearance for Potential Acquisition of Pincell S.r.l.

Scinai Immunotherapeutics (NASDAQ: SCNI) has received Italian government clearance under the Golden Power regulation for its potential acquisition of Pincell S.r.l., an Italian biotech company. The approval, granted after review by the Coordination Group and Ministry of Health, removes a major regulatory hurdle for the acquisition planned since March 2025. Pincell's key asset is PC111, a human monoclonal antibody targeting Fas/FasL pathway for severe dermatological conditions, which has received EMA Orphan Drug Designation for Pemphigus. Scinai's Polish subsidiary has applied for a €12 million FENG grant to fund PC111's development, with a decision expected by August 2025. The acquisition's completion remains contingent on successful grant approval and other customary conditions.

https://www.stocktitan.net/news/SCNI/scinai-immunotherapeutics-receives-italian-government-clearance-eck7jvaqpk1z.html